Search Icon
Search Icon
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

General

Scientists Sue Over ‘Discriminatory’ Retraction Of Studies Exposing Abortion Pill Dangers

Scientists are suing an academic publishing company for retracting three key studies exposing the dangers of the nation’s most popular abortion drug regimen shortly before the U.S. Supreme Court was slated to hear arguments in a landmark mifepristone case.

Ten of the researchers responsible for producing the three scientific papers filed a petition to compel arbitration this week against Sage Publications for issuing what they called “pretextual and discriminatory” retractions of their findings on the abortion pill. One of the studies in question, which the lawsuit notes is “the second most-read article” in the journal’s history, specifically determined mifepristone is responsible for a 500 percent increase in abortion-related emergency room visits.

Continue Reading at The Federalist >>

Latest Posts

October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined. Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

You Might Also Be Interested In

Graphic featuring a series of black horizontal brushstrokes leading into a circular geometric pattern, followed by the letters FDA in a stylized font, set against a white crinkled paper background for a peer-reviewed article on the abortion drug.

Peer-Reviewed Article: FDA Lacked Evidence to Drop In-Person Abortion Drug Requirement

charlotte-lozier-institute Charlotte Lozier Institute
October 6, 2026

Abortion Reporting: Ohio (2025)

A stylized white geometric design resembling a circular burst is centered over a dark blue map outline of the United States, highlighting the complexities of U.S. law and FDA safety limits around online abortion drug sellers.

New CLI Report: Online Abortion Drug Sellers Violating U.S. Law and FDA Safety Limits

charlotte-lozier-institute Charlotte Lozier Institute
May 26, 2026

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image